Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.

doi:10.1097/JTO.0000000000000125

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2014

Isobe Kazutoshi, Hata Yoshinobu, Tochigi Naobumi, Kaburaki Kyohei, Kobayashi Hiroshi, Makino Takashi, Otsuka Hajime, Sato Fumitomo, Ishida Fumiaki, Kikuchi Naoshi, Hirota Nao, Sato Keita, Sano Go, Sugino Keishi, Sakamoto Susumu, Takai Yujiro, Shibuya Kazutoshi, Iyoda Akira, Homma Sakae

Abstract excerpt

BACKGROUND: Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can have a crucial role in tumor response to treatment. To determine the clinical utility of detecting BIM deletion polymorphism in non-small-cell lung cancer positive for epidermal growth factor receptor (EGFR) mutation, we examined outcomes of patients with and without BIM alterations. METHODS: We studied 70 patients with EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis Regulatory Proteins

Share to Bcl-2-Like Protein 11

Share to Carcinoma, Non-Small-Cell Lung

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 24736070
DOI: 10.1097/JTO.0000000000000125
PMCID: PMC4132037

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.PMID 24736070Read ↗

Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.Semantic proximity Read ↗

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.Semantic proximity Read ↗

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.Semantic proximity Read ↗

The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.Semantic proximity Read ↗

Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations.Semantic proximity Read ↗

Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.Semantic proximity Read ↗

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.Semantic proximity Read ↗

Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.Semantic proximity Read ↗

EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.Semantic proximity Read ↗

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.